Topics:

Glaxo nabs FDA approval for hep C remedy Promacta

Tools

GlaxoSmithKline has won an FDA approval to market Promacta to hepatitis C patients whose low blood platelet counts prevent them from taking interferon, a commonly used treatment linked to a host of side effects. The approval marks a positive step for GSK ($GSK), which cited this R&D program as one of its most promising in the late-stage pipeline. And it significantly boosted shares of Ligand Pharmaceuticals ($LGND), which licensed the thrombocytopenia therapy to GSK back in 2008. Report